MOA
Semaglutide is a
glucagon-like peptide-1 receptor agonist. By mimicking the action of the
incretin glucagon-like peptide-1 (GLP-1), it increases the production of
insulin, the hormone that lowers the
blood sugar level.
[27] It also appears to enhance growth of pancreatic
beta cells, which are responsible for insulin production and release.
[28][29] Additionally, it inhibits the production of
glucagon, the hormone that increases
glycogenolysis (release of stored carbohydrate from the liver) and
gluconeogenesis (synthesis of new glucose). It reduces food intake by lowering appetite and slowing down digestion in the stomach,
[30] helping reduce body fat.
[31] It reduces hunger, food craving, and body fat.
[32][33]
Lowering Glucagon
Glucagon is a
peptide hormone, produced by
alpha cells of the
pancreas. It raises the concentration of
glucose and
fatty acids in the bloodstream and is considered to be the main
catabolic hormone of the body.
[3] It is also used as a
medication to treat a number of health conditions. Its effect is opposite to that of
insulin, which lowers extracellular glucose.
[4] It is produced from
proglucagon, encoded by the
GCG gene
It also increases glycemic control in type 1 diabetics. which you would normally do through insulin injections.
"Perfect glycemic control" would mean that glucose levels were always normal (70–130 mg/dL, or 3.9–7.2 mmol/L) and indistinguishable from a person without diabetes. In reality, because of the imperfections of treatment measures, even "good glycemic control" describes blood glucose levels that average somewhat higher than normal much of the time. In addition, one survey of type 2 diabetics found that they rated the harm to their quality of life from intensive interventions to control their blood sugar to be just as severe as the harm resulting from intermediate levels of diabetic complications
Hope this answered your question. All of this was taken from wiki so I just didn't have to type all of it.